Skip to content
+49 3371 6199600info@celltrend.deIm Biotechnologiepark 3 TGZ II, 14943 Luckenwalde
  • Contact
  • German
  • English
topbar - English
Search:
Suche
CellTrend Luckenwalde
Auftragsforschung, Antikörperdiagnostik
CellTrend LuckenwaldeCellTrend Luckenwalde
  • Company Profile
    • Newsroom
    • Board of management
    • Quality Management System
    • Referenzen
    • Partners
  • POTS – CFS/ME – SFN – Long Covid
    • Information for patients
  • AT1R-Antibody ELISA
    • Product information
    • Transplantation
    • Systemic sclerosis
    • Literature
  • ELISA
    • GPCR-Antibodies
    • In vitro Diagnostics (human)
    • Research use only
    • Food analysis
    • Contract research
    • Contract manufacturing
  • Consulting
  • Fluorescent Cells
  • Cell culture test systems
    • Oncology
    • Inflammatory test systems
    • Contract research
  • Company Profile
    • Newsroom
    • Board of management
    • Quality Management System
    • Referenzen
    • Partners
  • POTS – CFS/ME – SFN – Long Covid
    • Information for patients
  • AT1R-Antibody ELISA
    • Product information
    • Transplantation
    • Systemic sclerosis
    • Literature
  • ELISA
    • GPCR-Antibodies
    • In vitro Diagnostics (human)
    • Research use only
    • Food analysis
    • Contract research
    • Contract manufacturing
  • Consulting
  • Fluorescent Cells
  • Cell culture test systems
    • Oncology
    • Inflammatory test systems
    • Contract research

recommendation NINDS

You are here:
  1. Home
  2. News
  3. recommendation NINDS

The US National Institute of Neurological Disorders and Stroke (NINDS), one of the most renowned neuroscience research institutes, has included our antibody determinations in its recommendations for the diagnosis of CFS / ME.

F2765_Laboratory_Tests_Immune_Module.pdf (291,0 KiB)

2. July 2018

News
  • Last shipment day on December, 20th 2022 14. December 2022
  • Christmas Holidays 6. December 2022
  • ARD camerateam at CellTrend 12. November 2022
  • Apheresis against Long-COVID? 4. November 2022
  • CellTrend article in the MAZ 28. October 2022
  • New study about dysregulated autoantibodies in Post COVID Syndrome published 27. October 2022
+49 3371 6199600 info@celltrend.de Im Biotechnologiepark 3 TGZ II, 14943 Luckenwalde
  • Data protection declaration
  • Imprint
bottombar - English

FacebookInstagram

Go to Top